IP Library Granted Patent US 7,589,212
Granted Patent B2
US 7,589,212 · App. 11/821,868 · Granted Sep 15, 2009

Human protein tyrosine phosphatase inhibitors and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,589,212
App. No.
11/821,868
Granted
Sep 15, 2009
Kind
B2
Abstract

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

Claims (78)

1. A compound of the formula:

wherein R is a unit chosen from:

i) hydrogen;

ii) substituted or unsubstituted phenyl; and

iii) substituted or unsubstituted heteroaryl ring;

Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula:

R 1 is chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, branched, or cyclic alkyl;

iii) substituted or unsubstituted C 6 or C 10 aryl;

iv) —OR 4 ;

v) —C(O)OR 5 ;

vi) —COR 6 ;

vii) —NR 7 C(O)OR 8 ; and

viii) substituted or unsubstituted heteroaryl;

R 4 is hydrogen or substituted or unsubstituted C 1 -C 6 linear, branched, or cyclic alkyl; R 5 is C 1 -C 6 linear or branched alkyl, or benzyl; R 6 is C 1 -C 6 linear, branched, or cyclic alkyl, or phenyl; R 7 is hydrogen or methyl; R 8 is C 1 -C 6 linear or branched alkyl, or benzyl;

L is a unit having the formula —[C(R 9a R 9b )] y —;

R 9a and R 9b are each independently hydrogen, C 1 -C 6 linear or branched alkyl, or phenyl;

and the index x is 0 or 1; the index y is from 1 to 4;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R is phenyl.

3. A compound according to claim 1 wherein R is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl ,1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

4. A compound according to claim 3 wherein R is thiophene-2-yl or thiophene-3-yl.

5. A compound according to claim 1 wherein R 1 is chosen from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and cyclopropylmethyl.

6. A compound according to claim 1 wherein L has the formula —CH 2 —.

7. A compound according to claim 6 wherein R 1 is chosen from substituted or unsubstituted phenyl, naphthalen-1-yl, and thiazol-4-yl, said substitutions chosen from methyl, ethyl, n-propyl, hydroxy, hydroxymethyl, methoxy, fluoro, chloro, and trifluoromethyl.

8. A compound according to claim 7 wherein R 1 is chosen from phenyl, naphthalen-1-yl, 3-methoxyphenyl, and 2-methylthiazol-4-yl.

9. A compound chosen from:

(S)-{4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid;

(S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfamic acid;

4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

5-(3-Methoxybenzyl)-N-((S)-2-(4-nitrophenyl)-1-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)-1,3,4-thiadiazol-2-amine;

4-((S)-2-(5-(Naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid; and

4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid.

10. A composition comprising:

A) one or more compounds of the formula:

wherein R is a unit chosen from:

i) hydrogen;

ii) substituted or unsubstituted phenyl; and

iii) substituted or unsubstituted heteroaryl ring;

Z is a substituted or unsubstituted [1,3,4]thiadiazol-2-yl unit having the formula:

R 1 is chosen from:

i) hydrogen;

ii) substituted or unsubstituted C 1 -C 6 linear, branched, or cyclic alkyl;

iii) substituted or unsubstituted C 6 or C 10 aryl;

iv) —OR 4 ;

v) —C(O)OR 5 ;

vi) —COR 6 ; and

vii) —NR 7 C(O)OR 8 ; and

viii) substituted or unsubstituted heteroaryl;

R 4 is hydrogen or substituted or unsubstituted C 1 -C 6 linear, branched, or cyclic alkyl; R 5 is C 1 -C 6 linear or branched alkyl, or benzyl; R 6 is C 1 -C 6 linear, branched, or cyclic alkyl, or phenyl; R 7 is hydrogen or methyl; R 8 is C 1 -C 6 linear or branched alkyl, or benzyl;

L is a unit having the formula —[C(R 9a R 9b )] y —;

R 9a and R 9b are each independently hydrogen, C 1 -C 6 linear or branched alkyl, or phenyl; and the index x is 0 or 1; the index y is from 1 to 4;

or a pharmaceutically acceptable salt thereof; and

B) one or more excipients or carriers.

11. A compound according to claim 1 , wherein the compound is a pharmaceutically acceptable salt of either basic groups or acid groups.

12. A compound according to claim 11 , wherein the compounds are salts chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.

13. A compound according to claim 11 , wherein the compounds are salts chosen from ammonium, sodium, lithium, potassium, calcium, magnesium, and bismuth.

14. A composition according to claim 10 , wherein R is phenyl.

15. A composition according to claim 10 , wherein R is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophene-2-yl, thiophene-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl.

16. A composition according to claim 10 , wherein R is thiophene-2-yl or thiophene- 3-yl.

17. A composition according to claim 10 , wherein R 1 is chosen from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and cyclopropylmethyl.

18. A composition according to claim 10 , wherein L has the formula —CH 2 —.

19. A composition according to claim 10 , wherein R 1 is chosen from substituted or unsubstituted phenyl, naphthalen-1-yl, and thiazol-4-yl, said substitutions chosen from methyl, ethyl, n-propyl, hydroxy, hydroxymethyl, methoxy, fluoro, chloro, and trifluoromethyl.

20. A composition according to claim 10 , wherein R 1 is chosen from phenyl, naphthalen-1-yl, 3-methoxyphenyl, and 2-methylthiazol-4-yl.

21. A composition according to claim 10 , wherein the one or more compounds are chosen from:

(S)-{4-[2-(5-methyl-[1,3,4]thiadiazol-2-ylamino)-2-(4-phenylthiazol-2-yl)-ethyl]phenyl}sulfamic acid;

(S)-4-(2-(5-Phenyl-1,3,4-thiadiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl)-phenylsulfamic acid;

4-((S)-2-(5-Propyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

4-((S)-2-(5-Benzyl-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

5-(3-Methoxybenzyl)-N-((S)-2-(4-nitrophenyl)-1-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)-1,3,4-thiadiazol-2-amine;

4-((S)-2-(5-(Naphthalen-1-ylmethyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid;

4-((S)-2-(5-((Methoxycarbonyl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid; and

4-((S)-2-(5-((2-Methylthiazol-4-yl)methyl)-1,3,4-thiadiazol-2-ylamino)-2-(2-(thiophen-2-yl)thiazol-4-yl)ethyl)phenylsulfamic acid.

22. A composition according to claim 10 , wherein the compounds of the formula are in the form of pharmaceutically acceptable salts chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, and citrate.

23. A composition according to claim 10 , wherein the compounds of the formula are in the form of pharmaceutically acceptable salts chosen from ammonium, sodium, lithium, potassium, calcium, magnesium, and bismuth.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2020
From: AERPIO THERAPEUTICS LLC
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 052432/0789 →
CHANGE OF NAME Recorded Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049922/0273 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2012
From: AKEBIA THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 027796/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2011
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS INC.
Reel/Frame 027445/0100 →
PATENT RELEASE Recorded Dec 23, 2011
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 027443/0164 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →
SECURITY AGREEMENT Recorded Nov 2, 2009
From: WARNER CHILCOTT COMPANY, LLC
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023456/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: AMARASINGHE, KANDE K. D.; CLARK, CYNTHIA MONESA; NICHOLS, RYAN MATTHEW; MAIER, MATTHEW B.
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 022254/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2007
From: GRAY, JEFFREY LYLE
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 020202/0254 →